The study of Laursen et al. [13] demonstrated the growth-inhibitory effects of rituximab, a monoclonal antibody, which is used as a standard therapy to treat DLCBL [46], increased by AMD3100, supporting the negative impact of CXCR4 on the chemo-sensitivity of lymphomas cells. The gene discussed is CXCR4; the disease is lymphoma.